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Abstract. Pyrrolobenzodiazepine (PBD) derivatives are highly potent sequence-speciﬁc DNA cross-
linking agents. The present study aimed to identify key physicochemical properties inﬂuencing the
interaction of a series of PBDs (four dimers and 12 monomers) with the three major human ATP-binding
cassette (ABC) transporters (P-gp, ABCG2, and MRP1). Isogenic cell lines expressing P-gp and
ABCG2, cell lines with acquired resistance to cytotoxic agents due to the high expression of ABC
transporters, and speciﬁc inhibitors against P-gp, ABCG2, and MRP1 were used. P-gp and ABCG2
decreased the permeability of the PBD dimers across cell membranes and their interaction with DNA,
reducing DNA damage and the overall cytotoxic effect. PBD monomer SG-2823 formed a conjugate with
glutathione and interacted with MRP1, reducing its cytotoxic effect in A549 cells. Structure–activity
relationship revealed that the interaction of PBDs with the transporters could be predicted considering
the molecular weight, the lipophilicity, the number of (N+O) atoms and aromatic rings, the polar surface
area, the hydrogen bonding energy, and electrophilic centers. A rational design of novel PBDs with
increased potency and reduced interaction with the ABC transporters is proposed.
KEY WORDS: ABCG2; glutathione; MRP1; P-glycoprotein; structure–activity relationship.
INTRODUCTION
Cellular resistance is considered to be a major cause of
failure of chemotherapy treatment in patients with cancer (1,2).
Resistance mechanisms can be divided in two main groups. The
ﬁrst group includes factors altering the drug disposition of
anticancer agents, modifying their pharmacokinetic or the drugs
access to certain areas of the body (blood brain barrier for
example) (3); the second group includes factors altering the
antitumor effects of drugs (4). ABC transporters form a
superfamily of proteins implicated in both groups of resistance
mechanisms. Three major ABC transporters have been studied:
P-gp also termed multidrug resistance 1 (MDR1) or ABCB1,
ABCC1 commonly referred as multidrug resistance protein 1
(MRP1) and ABCG2 also named breast cancer resistance
protein. These transporters form large tridimensional structures
spanning the cell membrane and exclude endogenous and
exogenous chemical entities from the cell in an ATP-dependent
fashion. Genetic polymorphisms of both ABCB1 and ABCG2
have been correlated with alterations of pharmacokinetics of
anticancer agents and other therapeutics (3). However, ABC
transporters have mainly been studied for their overexpression
in multiple tumor types leading to multidrug resistance (MDR),
thereby decreasing the intracellular concentrations of anticancer
agents or increasing their detoxiﬁcation by cancer cells.
A wide variety of drugs, structurally dissimilar and
belonging to various therapeutic classes interact with ABC
transporters. However, for speciﬁc therapeutic classes with
low therapeutic indexes such as anticancer drugs, HIV-
protein inhibitors, antibiotics, or immunosuppressants, the
impact of drug transporters may have signiﬁcant consequences
(1). As part of the drug discovery activities, it is, therefore, key
to minimize the interaction of compounds with ABC trans-
porters to optimize both their pharmacokinetic and their
biological activity. Understanding of parameters controlling
these interactions is crucial for drug optimization.
SJG-136 is a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)
dimer forming DNA crosslinks spanning six base pairs with a
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preference for purine-GATC-pyrimidine sequences (5–7). SJG-
136 is extremely potent and showed cytotoxic effects at nM
concentrations in a broad variety of tumor types in vitro and
antitumor effects in xenograft models in vivo (5,8). SJG-136 is a
P-gp substrate, which reduces its cytotoxic effect in cancer cells
expressing high levels of P-gp (9). PBD monomers have shown
signiﬁcant cytotoxic effects in vitro in a number of tumor types
despite the absence of crosslinks formation and preclinical
studies have highlighted the potency of the PBDmonomers in a
number of tumor types (10–12). However, their interaction with
ABC transporters is unknown. SJG-136 is the ﬁrst PBD to enter
clinical development and is currently being assessed in Phase II
clinical trials (5,7,13).
This study evaluates the interactions of both PBD dimers
and monomers with ABC transporters P-gp, MRP1, and
ABCG2 and presents a strategy to optimize further this
promising class of anticancer agents.
MATERIALS AND METHODS
Materials
The PBD derivatives were synthesized through multiple
step synthesis that has been described in full elsewhere
(10,14,15). Aliquots were obtained from Spirogen Ltd
(London, UK). MK-571 was obtained from (BioMol Interna-
tional, Exeter, UK). Transwell plates with polyethylene
terephthalate membrane (Millicell 24) were obtained from
Millipore (Watford, UK). Hanks buffer balanced saline
(HBSS) was obtained from Fisher/Thermo Scientiﬁc
HyClone (Cramlington, UK). Lucifer yellow was obtained
from Molecular Probes (Invitrogen, Paisley, UK). All other
chemicals were obtained from Sigma–Aldrich (Poole, UK).
Phospho-histone H2AX (Ser 139) rabbit antibody was
obtained from cell signaling (New England Biolabs, Hitchin,
UK). Goat anti-rabbit FITC-conjugated was obtained from
Abcam (Cambridge, UK).
Cell Culture
Adenocarcinoma cell line Caco-2, colon cancer cell lines
HCT 116, HCT-15, and lung cancer cell line A549 were
obtained from the American Type Cell Culture Collection
(Rockville, Maryland) and European Collection of Cell
Cultures (Salisbury, UK). Ovarian cancer cell line A2780
and drug resistant sub-clones A2780AD were provided by the
National Cancer Institute (Bethesda, Maryland). Murine
ﬁbroblasts (3T3 GP+E86) and 3T3 transfected with c-DNA
expressing P-gp were kindly provided by Dr. E. Schuetz from
St. Jude’s Children Research Hospital (Memphis, Tennessee).
Breast cancer cell line MDA-MB-231 transfected with an
empty vector (MDA-MB-231/V8) and MDA-MB-231
transfected with c-DNA expressing ABCG2 (MDA-MB-231/
R12) were kindly provided by Dr. D. Ross from the
University of Maryland (Baltimore, Maryland). Breast
cancer cell line MCF7 and mitoxantrone (MX)-resistant sub-
clones MCF7-MX were kindly provided by Dr. E. Schneider
from the University of Maryland (Baltimore, Maryland).
HCT 116, HCT-15, A2780, and A2780AD were grown in
monolayer in RPMI 1640 medium supplemented with 5% v/v
fetal calf serum (FCS). 3T3 GP+E86, A549, MCF7, and
MDA-MB-231 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% FCS.
Caco-2 cells were grown in DMEM with a high glucose
content (4.5 g/L) supplemented with 10% FCS. A2780AD
cells are derived from the parental A2780 cell line and are
resistant to doxorubicin. They were obtained by stepwise
incubation of increasing concentration of doxorubicin (16).
They were maintained in 10−7 M doxorubucin and were drug-
free 1 week prior to any experiment. MCF7-MX cells are
derived from the parental MCF7 cell line and are resistant to
mitoxantrone. They were obtained by stepwise incubation of
increasing concentration of mitoxantrone (17). They were
maintained in 10−8 M mitoxantrone and were drug-free
1 week prior to any experiment. MDA-MB-231 cells were
maintained in 1 mg/mL of G418 sulfate and were antibiotic-
free 1 week prior to any experiment. All cells were tested
regularly for mycoplasma contamination and were
mycoplasma-free for the period of the study.
Cytotoxicity Assay
Drug concentrations that inhibited 50% of cell growth
(GI50) were determined using a sulforhodamine B technique
as described elsewhere (18). All cell lines were treated for
24 h on day 2 and allow growing for an additional 3 days.
When cells were pretreated with different inhibitors (50 μM
MK-571, 10 μM Fumitremorgin C, 100 μM dicumarol), cells
were treated 1 h before drug exposure (24 h prior to the
experiment for L-buthionine–sulfoximine, 10 μM). Optical
densities were measured at 540 nm with a Biohit BP-800
(Bio-Hit, Helsinki, Finland). Growth inhibition curves were
plotted as percentage of control cells, and GI50 values were
determined by Graphpad Prism 4 Software (San Diego,
California) by ﬁtting a sigmoidal curve with variable slope.
Immunostaining for γ-H2AX
Exponentially growing A2780AD cells were seeded in
chamber slides on day 1. The cells were treated on day 3 with
10 nM of DRG-16 for 24 h. When cells were pretreated with
verapamil, they were treated with 5 μg/mL verapamil starting
1 h before drug exposure. Cells were washed in PBS and then
incubated in 2% paraformaldehyde in PBS for 10 min,
washed in PBS, permeabilized in 0.1% triton X100, diluted
in PBS at room temperature (RT) for 10 min, washed,
blocked with PBS containing 1% bovine serum albumin,
and incubated overnight at 4°C with an anti-phosphohistone
H2AX antibody, washed, incubated with a FITC, AlexaFluor
488-conjugated goat anti-mouse IgG antibody for 1 h at RT,
and washed in PBS. Slides were mounted and visualized with
a Leitz Laborlux UV microscope (Wetzlar, Germany) using a
×40 objective ﬁtted with a Spot Insight 4 camera (Diagnostic
Instruments, Sterling Heights, Michigan). The intensity of
ﬂuorescence was evaluated with Photoshop CS3 (Adobe
Systems Incorporated, San Jose, California).
Transwell Assay
Caco-2 cells were seeded on to cell culture chambers
(transwells) for 21 days, and the media changed every other
day. The transepithelial electric resistance was measured
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using an epithelial voltohmmeter equipped with an STX2
electrode (World Precision Instruments, Sarasota, Florida),
and it was veriﬁed to be >300 Ω/cm2 prior to all experiments.
The assay was started by replacing the culture medium with
HBSS containing 1 μM of drug. The plates were placed on an
orbital shaker (60 rpm) during the experiment. After 2 h, a
volume of 10 μL of each chamber was collected for analysis
by LC/MS. The permeability of a test compound was deﬁned
by the following equation (Eq. 1) (19):
Papp ¼ dQ=dtð Þ=AC0 ð1Þ
Where A is the surface area of the transwell membrane,
C0 is the molar drug concentration in the donor chamber at
time and dQ/dt is the rate of transfer of the compound to the
receiver chamber, determined from the slope of the graph
concentration (dQ) versus time (dt).
It has been stated that if a compound exerts a ratio
between the secretion (permeability from the basal to the
apical side (Papp B→A)) and the absorption (permeability
from the apical to the basal side (Papp A→B))>3, it can be
considered as being actively efﬂuxed (20). At the end of the
assay, the integrity of the monolayer was veriﬁed by measur-
ing the amount of lucifer yellow, a ﬂuorophore, which has
passed through the membrane using a plate reader (Wallac
EnVision reader, PerkinElmer, Massachusetts) and veriﬁed to
be <2% of the concentration in the donor chamber (21,22).
The integrity of the monolayer was assessed post-drug
transport as lucifer yellow may interfere with LC/MS analysis.
Detection of Glutathione-Conjugated SG-2823
SG-2823 (10 μM) was incubated with GSH (1 mM) for
15 min at RT in cell-free HBSS. The products of the reaction
were analyzed by LC/MS. The HPLC system comprised of a
Dionex 3000 Ultimate series LC (Sunnyvale, California)
connected to a 4000 Q Trap LC-MS/MS system (Applied
Biosystems, Foster City, California), equipped with an
orthogonal electrospray ion source. Data were acquired and
processed with Chromeleon 6.1 (Dionex, Sunnyvale, Califor-
nia) and Analyst 1.4 chromatography manager software
(Applied Biosystems, Foster City, California). Compounds
were separated on a Dionex Acclaim® C16 (150×2.0 mm I.
D.) and 3 μm particle size column protected by a
Phenomenex Gemini® C18 (4.0×2.0 mm I.D.) and 3 μm
particle size guard cartridge (Phenomenex, Torrance,
California). The HPLC method used gradient elution;
mobile phase solvent A was water with 0.1% formic acid,
and mobile phase B was acetonitrile with 0.1% formic acid.
The initial mobile phase composition of 99% solvent A and
1% solvent B was maintained for 3 min. Between 3 and
9 min, the percentage of mobile phase B was increased to
75%, kept constant for 2 min, and then back to the initial
mobile phase composition within 2 min, with a total run time
of 16 min. The column was set at a ﬂow rate of 0.23 mL/min
and a temperature of 33°C. A sample volume of 6 μL was
used for all LCMS experiments. The mass spectrometer
was operated in electrospray mode. The source temperature
was 450°C, and the spray voltage of 3 kV was used. The
collision gas pressure was 1.5 mTorr. All analytes were
optimized using the Analyst software auto tune facility for
SRM transitions with dwell times set at 75 ms.
Analysis of the Hydrogen Bond Acceptor Patterns
The three-dimensional structures of compounds were
modeled with a modiﬁed version of Allinger’s MM2 force
ﬁeld approach, using the software Chem3D (Cambridge Soft
Corporation, Cambridge, Massachusetts) (23). The chemical
structures were then screened for electron donor groups (i.e.,
O, N, S). The spatial distance between neighboring atoms
carrying the free electron pair was measured. The hydrogen
bond acceptor pattern was determined and quantiﬁed as
formed either by two electron donor groups separated by a
spatial distance of 2.5±0.3 Å or two electron donor groups
separated by 4.6±0.6 Å or three electron donor groups
separated by 4.6±0.6 Å, as described by Seelig et al. (24). In
order to quantify the hydrogen bond acceptor pattern,
relative hydrogen bond energy units were assigned: an
oxygen-containing electron donor group equal 1 while a
weaker oxygen-free electron donor group was 0.5 (24).
Determination of LogP, PSA, and Partial Charge
The hydrophobicity of the molecules, LogP, the polar
surface area (PSA), deﬁned by as a sum of surfaces of polar
atoms (usually oxygen, nitrogen, and attached hydrogen), and
the partial charge (measured by the extended Hückel
calculation) were also determined using Chem3D.
Surface Activity
Experiments were carried out as previously described
(25). Water used for buffers and solutions was nanopure with
a resistivity of 17.5 MΩ/cm. Tris buffer (50 mM, containing
114 mM NaCl) was adjusted with HCl to the desired pH of
7.4. The surface pressure was measured at 23±1°C using a
teﬂon trough (3–5 mL ﬁlling volume, Nima Technology Ltd,
Coventry, UK) and a Wilhelmy plate covered by a plexiglas
hood to minimize evaporation and using drug concentrations
ranging from 10−4 to 10−6 M. DMSO, used as a solvent, was
tested to correct for its own surface activity. The measurements
were monitored using aDST9005 tensiometer (Nima Technology
Ltd, Coventry, UK).
RESULTS
P-gp and ABCG2 Decreases the Growth Inhibitory Effect of
PBD Dimers
The potential interactions of PBD dimers with ABC
transporters P-gp and ABCG2 was assessed using isogenic
cell lines expressing the cDNA for the respective trans-
porters. The growth inhibitory effect of four PBD dimers
SJG-136, DSB-120, DRG-16, and ELB-21 (Fig. 1a) was
determined in 3T3 cells expressing an empty vector (3T3
GP+E86) or the cDNA of P-gp (pHamdr1) and MDA-MB-
231 expressing vector control (V8) or the cDNA of ABCG2
(R12). In the P-gp overexpressing set of cell lines, the ratio of
GI50s ranged from 33 to 46 (Fig. 2a). In MBD-MB-231/V8
and R12, the ratio of GI50s ranged from 3.4 to 4.1 (Fig. 2b).
These results suggest that overexpression of P-gp or ABCG2
impairs the cytotoxic effect of PBD dimers.
619SAR of the PBDs for ABC Transporters
The isogenic cell lines used in the ﬁrst experiment express
nonphysiological levels of the transporters. Additionally,
resistance due to transporter expression can occur intrinsically
in tumors derived from tissue normally expressing high levels
of transporters (colon for example) or after exposure of cancer
cells to cytotoxic agents (acquired resistance). The PBD dimers
were, therefore, tested in cell lines mimicking these two
situations. HCT 116 and HCT-15 are colon cancer cell lines,
but only HCT-15 expresses high levels of P-gp. A2780AD is an
ovarian cell line derived from the parental cell line A2780 and
resistant to doxorubicin after in vitro exposure to the drug.
Similarly, MCF7-MX presents an acquired resistant to
mitoxantrone. The ratio of GI50s between HCT 116 and
HCT-15 ranged from 2.3 for DSB-120 to 7.8 for ELB-21
(Table I). The ratio of GI50s in A2780
AD and A2780 was
greater than 50-fold for all PBD dimers (Fig. 2c).
Resensitization was achieved by the addition of verapamil,
with ratios of GI50s in presence and absence of verapamil
ranging from 4.2 for SJG-136 and 6.4 for DRG-16 (Fig. 2c). A
similar pattern was observed for ABCG2 with a ratio of GI50s
Fig. 1. Chemical structure of PBD dimers (a) and PBD monomers (b) analogs investigated. The carbons
C2 the C11 have been marked for reference in the text
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Fig. 2. Impact of ABC transporters, P-gp and ABCG2 on the growth inhibitory effect of the PBD dimers.
a Ratios of GI50 in pHamdr1 cells (overexpressing P-gp) and 3T3 parental cells. b Ratio between the GI50
observed in MDA-MB-231/R12 cells, (transfected with cDNA-ABCG2) and in MDA-MB-231/V8 cells
(transfected with an empty vector). Vinblastine (negative control) and mitoxantrone (positive control) are
presented for comparison. c Impact of P-gp inhibition on the cytotoxic effect of PBD dimers in A2780 and
A2780AD. Ratio between the GI50 observed in A2780p and A2780
AD (white bars); Ratios of GI50 for PBD
dimers in presence and absence of verapamil in A2780AD (gray bars). d Ratio of GI50 for PBD dimers
between MCF7 and MCF7-MX. All results are mean of ratios ± SEM of at least three experiments
performed in triplicate
Table I. Sensitivity of HCT 116 and HCT-15 Cells to Pyrrolobenzodiazepine Derivatives
HCT 116 HCT-15 Ratios GI50 HCT-15 and GI50 HCT 116
a
GI50 (nM) SD GI50 (nM) SD Ratios SD
SJG-136 0.72 0.24 2.5 0.46 3.6 0.1
DSB-120 42 18 85 32 2.3 1
DRG-16 0.044 0.015 0.22 0.09 5.5 2
ELB-21 0.026 0.01 0.19 0.12 7.8 1
a Ratios between the GI50 in HCT-15 cells and the GI50 in HCT 116 cells are expressed as means between independent experiments. Results
are means of at least three independent experiments performed in triplicate
621SAR of the PBDs for ABC Transporters
in MCF7-MX compared to MCF7 greater than 30 for all PBD
dimers (Fig. 2d). ABCG2 substrate speciﬁcity of the PBD
dimers was conﬁrmed using FTC, a speciﬁc inhibitor of the
transporter (Supplementary data S1). Overall, PBD dimers
tested in these different cell lines show a reduced cytotoxic
effect in cell lines expressing high levels of P-gp or ABCG2.
PBD dimers crosslink the DNA and induce the forma-
tion of γH2AX foci at sites of DNA damage. To conﬁrm that
expression of P-gp had a direct impact of the ability of PBD
dimers to exert their mechanism of action, the presence of
γH2AX foci was determined in A2780 and A2780AD cells in
presence of DRG-16 ± verapamil (P-gp blocker). In A2780AD
cells, low levels of γH2AX foci were observed after exposure
to DRG-16. A 2-fold increase in the number of γH2AX foci
was observed in cells exposed to DRG-16 in presence of
verapamil (Fig. 3a and b). In A2780 cells, exposure to DRG-
16 induced a dose- and time-dependent formation of γH2AX
foci (data not shown).
Finally, the direct impact of the transporters on the PBD
dimers was assessed by measuring the permeability of two
PBD dimers SJG-136 and DRG-16 across a monolayer of
differentiated Caco-2 cells, the most extensively characterized
cell-based model to examine the permeability of drugs
(Fig. 3c). The permeability was measured from the apical to
the basal side (Papp A→B) and from the basal to the apical
side (Papp B→A). Both SJG-136 and DRG-16 show an efﬂux
Fig. 3. Impact of the ABC transporters on DNA damage and cell permeability of PBD dimers. a, b Impact
of P-gp inhibition on DNA damage observed in response to DRG-16. a A2780AD cells were exposed to
DRG-16 in presence (left) or absence of verapamil (right). Representative pictures of γH2AX foci (top in
green). Counterstain with DAPI conﬁrms the nuclear localisation of γH2AX foci (×40 magniﬁcation;
bottom in blue). b γH2AX foci formation as expressed by staining intensity. Results are means ± SEM of
50 cells. Statistical probability is expressed as ***p<0.001. c Impact of ABC transporters on the
permeability of the PBD dimers compared to P-gp substrate vinblastine as determined by the transwell
assay in Caco-2 cells. White bars correspond to passive diffusion (Papp A→B) and gray bars to efﬂux
(Papp B→A). The results are mean of ratios ± SEM of triplicate
bFig. 4. Impact of MRP1 on the cytotoxic effect of PBD monomers. a
Ratio of GI50 for PBD monomers in A549 cells in absence or
presence of MK-571. Results are means ± SEM of n=3 independent
experiments performed in triplicate. b Impact of GST inhibition on
the cytotoxic effect of SG-2823. A549 cells were treated with SG-2823
with (filled triangles, plain line) or without pretreatment with
dicumarol (filled squares, dotted line). Results are means ± SEM
idem of triplicate. c Impact of the inhibition of γ-glutamylcysteine
synthetase on the cytotoxic effect of SG-2823. A549 cells were treated
with SG-2823 with (filled triangles, plain line) or without pre-
treatment with BSO (filled squares, dotted line). Results are
means ± SEM idem of triplicate. d Analysis of the conjugation of
SG-2823 to glutathione in vitro by LC-MS. a Total ion chromatogram
for the cell-free analysis of GSH with SG-2823. b Spectra taken from
the peak at 3.99 min which corresponds to GSH [M+H]+308.5. c
Spectra taken from the peak at 8.8 min which identiﬁes the GSH
conjugate [M+H]+671.5. d Spectra taken from the peak at 9.77 min
which identiﬁes SG-2823 [M+H]+363.5
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ratio (Papp B→A/ Papp A→B) of 6.4 for SJG-136 and 3.5 for
DRG-16 consistent with both agents being actively trans-
ported by the ABC transporters.
PBD dimers, therefore, interact with ABC transporters
P-gp and ABCG2. This interaction decreases the drug uptake
into cancer cells, decreasing the levels of DNA crosslinks
generated by PBD dimers. Decreased DNA damage trans-
lated into a reduced cytotoxic effect. Overall, it suggests that
the antitumor activity of PBD dimers could be improved,
provided the interaction with ABC transporters is minimized.
The PBD monomer SG-2823 Interacts with MRP1, Causing
a Marked Effect on its Activity, But Only Weakly
with Other ABC Transporters
The cytotoxic effect (GI50) of 12 PBD monomers
(Fig. 1b) were tested in the non-small cell lung cancer cell
line A549, expressing high levels of MRP1 in presence or
absence of a MRP1 blocker, MK-571. Pretreatment with MK-
571 increased by a 5-fold factor the sensitivity of A549 cells to
SG-2823 (Fig. 4a). All other PBD monomers were unaffected.
MRP1-driven transport requires a prior conjugation with
glutathione via glutathione-S-transferase (GST). The impact
of both these factors was tested. The cytotoxic effect of SG-
2823 decreased when A549 cells where preincubated in
presence of 100 μM dicumarol, a GST inhibitor (Fig. 4b):
from 53 nM [95% conﬁdence interval=50–55 nM] for SG-
2823 alone to 11 nM [10–13 nM] in the presence of dicumarol.
A549 cells were also pretreated with buthionine sulfoximine
(BSO), a potent and speciﬁc inhibitor of γ-glutamylcysteine
synthetase, the rate-limiting enzyme in the synthesis of GSH
(26). The cytotoxic effect of SG-2823 decreased ∼2.4-fold
when A549 cells were pretreated with BSO: from 57 nM
[95% conﬁdence interval=50–63 nM] for SG-2823 alone to
24 nM [20–28 nM], in presence of BSO (Fig. 4c). Both
dicumarol and BSO had no effect on the cytotoxic effect of
another PBD monomer SG-2781 (Supplementary data S2).
Finally, the formation of SG-2823 conjugated to GSH was
evaluated in vitro and monitored by LCMS, identifying the
presence of GSH, SG-2823, and GSH-SG-2823 (Fig. 4d).
PBD monomers were also tested for their interaction with P-
gp and ABCG2. Overall, PBD monomers were less liable to
interaction with ABC transporters. However, SG-2823 inter-
acted signiﬁcantly with MRP1, decreasing its cytotoxic effect
in cells expressing high levels of MRP1 and was also a weak
substrate of P-gp and ABCG2 (Supplementary data S3).
Specific Physicochemical Properties of PBD Control
Their Interactions with ABC Transporters
Multiple chemical features and even pharmacophores
have been identiﬁed and explain, at least for some classes of
compounds, their interactions with P-gp. In this study, we
considered the number of nitrogen and oxygen, hydrogen
bonding energy, surface activity, polar surface area, lip-
ophilicity (LogP), and molecular weight (MW; Table II).
The PBD dimers had a number of nitrogen and oxygen atoms
(N+O) greater than 8, a hydrogen bonding energy (HBE)
between 15 and 17 U, a polar surface area for all PBD dimers
greater than 75 Å2, all suggesting that PBD dimers had
features previously identiﬁed in other P-gp substrates.
Additionally, both MW and lipophilicity showed a positive
correlation with the differential cytotoxicity in HCT 116 and
HCT-15 cells (low and high P-gp, respectively) suggesting that
lower lipophilicity and/or MW could potentially decrease the
interaction with P-gp (Fig. 5a and b). Conversely, the PBD
monomers had lower HBE, MW, PSA<75 Å2 consistent with
their weak/no interaction with P-gp. Seven out of 12 PBD
monomers were surface active (Table II). However, this was
not related to their differential cytotoxic effect.
To evaluate the potential interaction with ABCG2, a
number of parameters relative to the hydrophilic character-
istic, the electrophilic parameter and aromaticity of PBD-
dimers and monomers, were tested against their relative
cytotoxicity in MCF7-MX in presence and absence of FTC
(ABCG2 inhibitor). Arbitrary values were attributed to
Table II. Pyrrolobenzodiazepine Derivatives Chemical Features Involved in P-gp Substrate Speciﬁcity
MW LogP PSA
Hydrogen bond
acceptor pattern
Hydrogen bonding
energy
Basic
Nitrogen (N+O)
Surface
activity
2 Aromatic
rings
SJG-136 556.61 1.383 102.2 + 15 + 10 − +
DSB-120 532.58 1.295 102.2 + 15 + 10 − +
DRG-16 584.66 2.254 102.2 + 17 + 10 − +
ELB-21 612.71 2.989 102.2 + 17 + 10 − +
SG-2781 377.44 2.494 54.4 + 7.5 + 6 − +
SG-2796 360.41 2.844 51.1 + 7.5 + 5 − +
SG-2797 402.37 3.13 51.1 + 7.5 + 5 + +
SG-2819 376.45 3.443 51.1 + 7.5 + 5 + +
SG-2820 359.38 2.242 74.9 + 7.5 + 6 − +
SG-2823 362.38 1.956 68.2 + 7.5 + 6 − +
SG-2825 340.42 2.788 51.1 + 7.5 + 5 + −
SG-2897 385.42 2.292 64 + 7.5 + 6 − +
SG-2900 354.44 3.205 51.1 + 7.5 + 5 + −
SG-2901 368.47 3.622 51.1 + 7.5 + 5 + −
SG-2902 340.42 2.753 51.1 + 7.5 + 5 + −
SG-2003 348.39 2.493 51.1 + 7.5 + 5 + +
MW molecular weight; PSA polar surface area; (N+O) number of nitrogen and oxygen atoms
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nitrogen and oxygen atoms according to their electronega-
tivity. The electronegativity of the ﬂuoro groups were
considered as similar as an atom of nitrogen and given an
arbitrary value of 1 (the spatial distance between the different
atoms of ﬂuorine is too limited for them to make an impact as
separated entities). The electrostatic potential, i.e., partial
charge of the atoms, as determined by the extended Hückel
calculation was also taken into consideration as well as the
number of aromatic rings. The combination of all these
parameters led to deﬁne the following equation (Eq. 2):
ðn½1=2NþOmolecule þ n½1=2N þOC2aryl extremity
þ n½1=2N þOaromatic ringÞ ð2Þ
Where n(N−+O−) is the number of oxygen atoms that are
negatively charged as determined by the Hückel calculation.
The equation (Eq. 2) was associated with a signiﬁcant
correlation with the differential cytotoxic effect in MCF7-
MX (r2=0.98; p<0.0001; Fig. 6). PBD monomers associated
with a ratio −FTC vs +FTC<2 (SG-2796, SG-2819, 2900, SG-
2901, and SG-2902) were considered as non-substrates of
ABCG2 in contrast with all PBD dimers and the rest of the
PBD monomers. PBD non-substrates of ABCG2 had an
electrostatic potential <9 considering this value as a threshold
for ABCG2 substrate speciﬁcity.
Overall, the interaction of PBDs with ABCG2 could be
minimized by limiting C2 aryl substituents and the number of
aromatic rings.
DISCUSSION
This study evaluated the impact of ABC transporters on
a series of very potent PBD dimers and monomers and
potentially avenues to minimize this interaction. The PBD
dimer SJG-136 is currently in clinical development, and
promising results from preclinical studies suggest that the
optimization of this class of promising molecules could be
highly beneﬁcial for future drug development.
PBD dimers all had a signiﬁcant interaction with ABC
transporters. The analysis of the physicochemical properties
responsible for this interaction highlighted MW and lip-
ophilicity as the main factors controlling the degree of
interaction. All the PBD dimers and one PBD monomer
(SG-2797) had a MW greater than the accepted threshold of
400 (27), but the PBD monomer, SG-2797, was not consid-
ered to be a substrate for the ABC transporters on the basis
of the biological data. However, the MW cutoff does not take
into account the pKa of the molecules. The MW cutoff would
be lower for bases (28) and higher for acids (29) depending
on the ionization of the compounds. PBD derivatives are
weak acids (pKa=4.1), and this study suggests that the MW
cutoff for this class of compounds is likely to be higher than
400 but less than 533. Further studies with PBD monomers
and dimers could be undertaken to reﬁne this cutoff. Hydro-
phobicity is thought to be a major determinant in P-gp
substrate speciﬁcity (1,30,31). Molecules with LogP<1 or >5
are predicted to be non-substrates despite having some of the
physicochemical features of P-gp substrates (32). However,
some of these compounds have been shown to be P-gp
substrates by others (33–35). The data for the PBDs showed
that although LogP failed to discriminate substrates from
non-substrates, it could be used to evaluate the degree of P-
gp dependency, in conjunction with MW. Surface active
properties, which allow the compounds to partition into the
membrane and decrease the surface tension, were suggested
Fig. 5. Correlation between chemical features of PBD dimers and ratio of GI50 values in HCT 116 and
HCT-15. a Log P; b molecular weight
Fig. 6. Correlation between the units of electrostatic potential and
aromaticity of the PBDs involved in ABCG2 substrate speciﬁcity and
the ratio between the GI50 (FTC versus+FTC) in MCF7-MX cells. The
electronegative potential and aromaticity was deﬁned by the
following equation ðn½1=2NþOmolecule þ n½1=2N þOC2aryl extremityþ
n½1=2N þOaromatic ringÞ where n (N−+O−) is the number of oxygen
atoms that are negatively charged as determined by the Hückel
calculation
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to inﬂuence P-gp dependency (30). However, we found no
evidence that this was the case with PBDs. All the substrates
described by Seelig and Landwojtowicz were relatively basic
(pKa>7.4) and are more likely to be ionized in a relatively acid
environment (30). This ionized form is traditionally thought to
be membrane impermeable. The lipophilicity as described
among other parameters by the surface activity could compen-
sate and allow compounds such as PBD (when pH<pKa) to
interact with the membrane and being recognized by P-gp.
Other parameters such as polar surface area, number of
nitrogen and oxygen, hydrogen bonding energy, were all
consistent with previous literature on P-p substrates (30,32).
The PBDs with a greater number of oxygen and nitrogen
atoms and negatively charged (electrostatic potential) were
associated with greater substrate speciﬁcity for ABCG2.
ABCG2 substrates share a common set of physicochemical
properties such as a high polarity, a greater number of
aromatic rings and hydrophilic groups (36). The aromaticity
of the PBDs was of interest. SG-2897 was associated with the
greatest ratio (4.2) and also the greatest number of aromatic
rings among the PBD monomers. However, because of its
quinoline substituent, two phenomena could have had an
impact on ABCG2 substrate speciﬁcity. First, the electro-
negative group within the ring may be the prerequisite for an
enhanced interaction with the transporter. On the other hand,
the electrons, organized in π orbitals, may be shared with the
electrons of a surrounding planar group, thus inducing a
greater interaction. This phenomenon, representing the π–π
stacking interaction, as well as the electrophilic characteristic
was incorporated into Eq. 2 and demonstrated a signiﬁcant
correlation both for the PBD dimers and PBD monomers.
Overall, this study suggests that the PBDs bind to a
positively charged binding pocket of ABCG2, thus enhancing
electrostatic interactions. Similar ﬁndings have been reported
for a series of camptothecin analogs (36). ABCG2 is a “half
transporter” which needs to homodimerize in order to be
fully activated. Studies have shown that ABCG2 has at least
two symmetrical binding pockets (37). PBD dimers, high
afﬁnity substrates of the transporter (potential afﬁnity value
of 16) whereas some PBD monomers, without (N+O) atoms
at the C2 extremity, and being considered as the mono-
functional counterpart of PBD dimers for this property, have
an arbitrary potential ABCG2 afﬁnity value of 8, half of the
potential of PBD dimers. These data suggest that PBD dimers
may bind to the two symmetrical binding pockets of ABCG2.
The current study provided evidence that the PBD
monomer SG-2823 interacts with MRP1. The chemical
structure of SG-2823 seems likely to play a major role in the
ability of this compound to conjugate to GSH. SG-2823 has a
carbonyl moiety at its extremity which is an electrophile,
susceptible to nucleophile addition by GSH. However, the
conjugate would remain highly unstable. Alternatively, the
carbonyl group of SG-2823 may be involved indirectly in the
coupling: it may induce a delocalization of the electrons, thus
affording a greater electrophilicity of the C11. It may also
attract GSH at the carbonyl without creating any bond. This
induced proximity (between GSH and SG-2823) may allow
the SH group to interact with C11 of SG-2823 and create a
covalent bond. The mass spectrometry analysis identiﬁed the
intermediate compound with a MW of 671.5 g/mol which
corresponds to [M+H]+ of the proposed structures. The
PBDs, dimers and monomers, contain highly reactive imines
in the diazepinone portions of the molecule. Cheung and
colleagues have demonstrated that water or alcohol adds
readily to the imino moiety of the PBD dimer SJG-136 to
form the corresponding carbinolamine or its alkyl ether,
respectively (38). Similar results have been demonstrated
with the PBD monomers by Antonow and colleagues
(personal communication). The imine of the PBDs reacts
differentially with GSH, thus decreasing the potential for the
entity to react with the N2 of the guanine in the minor groove
of the DNA. The electrophilic centre of the PBDs at the C11
position allows these molecules to bind to DNA and exert
their antitumor activity, thus limiting the electrophilic
characteristic at the C2 extremity would appear to be the
best strategy to limit the detoxiﬁcation process mediated by
GSH, GST, and MRP1.
This study, therefore, provides a clear path for further
optimization: considering the MW of the building block for
the PBD dimers, it is unlikely that PBD dimers will have a
MW below 400. There is greater scope for the PBD
monomers: a molecule, associated with a MW<402, a PSA<
75 Å2, a HBE<10, an electrostatic potential <9, and lacking a
carbonyl moiety at the extremity, may overcome the
resistance mediated by the ABC transporters. Alternatively,
the pKa may be lowered in order to increase the thresholds
such as the MW. These properties should be combined with
the structural features involved in their activity (10), thus
allowing a rational design of new entities with enhanced
antitumor activity. As documented for other low afﬁnity
substrates, the PBD monomers would potentially be
associated with an increased oral absorption and systemic
bioavailability that will consequently increase the efﬁcacy of
the treatment (39–41).
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